Substance / Medication

Pirtobrutinib

Overview

Active Ingredient
pirtobrutinib
RxNorm CUI
2629338
Labeler: Eli Lilly and CompanyUpdated: 2025-12-04T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

None.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma.
Wang Michael L, Jurczak Wojciech, Zinzani Pier Luigi et al. · J Clin Oncol · 2023
PMID: 37192437ObservationalFull text (PMC)
Ganciclovir-resistant CMV encephalitis in a mantle cell lymphoma patient on pirtobrutinib: Case report.
Unterborn Rebecca, Brade Karrine, Bair Steven M et al. · IDCases · 2025
PMID: 41140916Case ReportFull text (PMC)
Pirtobrutinib in relapsed or refractory mantle cell lymphoma: outcomes from the compassionate use program in Italy.
Banegas Daniela Estefania, Ferrarini Isacco, Bernardelli Andrea et al. · Leuk Lymphoma · 2026
PMID: 41608968Other
Shifting clones: CLL evolution under pirtobrutinib treatment.
Jebaraj Billy Michael Chelliah, Stilgenbauer Stephan · Blood · 2026
PMID: 41477751Other
Bridging the Gap: Pirtobrutinib for Treatment-Naïve Chronic Lymphatic Leukemia.
Braunstein Marc J, Williams Michael E · J Clin Oncol · 2026
PMID: 41557975Other
Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R marginal zone lymphoma: phase 1/2 BRUIN study.
Patel Krish, Vose Julie M, Nasta Sunita D et al. · Blood Adv · 2026
PMID: 41544219Other
Genomic determinants of response and resistance to pirtobrutinib in relapsed/refractory chronic lymphocytic leukemia.
Brown Jennifer R, Nguyen Bastien, Desikan Sai Prasad et al. · Blood · 2026
PMID: 41055698TrialFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Pirtobrutinib (substance)
SNOMED CT
1351539006
UMLS CUI
C5554559
RxNorm CUI
2629338
Labeler
Eli Lilly and Company

Clinical Data

This intervention maps to 1 entities in the Healos knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.